Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9293762 | 0.84 | GAA (0.43) | GAAMAPT | |
| SCHEMBL6607968 | 0.72 | GAA (0.46) | GAAMAPT | |
| SCHEMBL2904681 | 0.72 | GAA (0.46) | GAAMAPT | |
| SCHEMBL21145451 | 0.68 | GAA (0.46) | GAAMAPT | |
| SCHEMBL4587067 | 0.68 | GAA (0.42) | GAAMAPT | |
| SCHEMBL20338456 | 0.68 | MAPT (0.42) | GAAMAPT | |
| SCHEMBL9281528 | 0.68 | GAA (0.42) | GAAMAPT | |
| SCHEMBL2255782 | 0.67 | MAPT (0.50) | GAAMAPT | |
| SCHEMBL29789697 | 0.67 | MAPT (0.50) | GAAMAPT | |
| SCHEMBL7159138 | 0.67 | MAPT (0.45) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560389-B2 | Heterocyclic inhibitors of monocarboxylate transporters | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210094969-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2021-04-01 | — | — | US | disclosed |
| US-10851113-B2 | Heterocyclic inhibitors of monocarboxylate transporters | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190330228-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-10-31 | — | — | US | disclosed |
| US-10329303-B2 | Heterocyclic inhibitors of monocarboxylate transporter | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180002343-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2018-01-04 | — | — | US | disclosed |
| EP-3247360-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | The Scripps Research Institute (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016118825-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-07-28 | — | — | WO | disclosed |
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1051176-B1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMA INC (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1051176-A4 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARM PROD INC (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| CN-1291892-A | Substituted oxoazaheterocyclyl factor Xa inhibitors | AWENTIS PHARMACEUTICAL INC (US) | 2001-04-18 | — | — | CN | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000032590-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002343-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | SLC16A1, SLC16A3, SLC16A7 | GAA 2114/4885MAPT 1112/4885 |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | GAA 566/4885MAPT 4874/4885 |
| US-10851113-B2 | Heterocyclic inhibitors of monocarboxylate transporters | SLC16A1, SLC16A3, SLC16A7 | GAA 1842/4885MAPT 1981/4885 |
| US-20210094969-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | SLC16A1, SLC16A3, SLC16A7 | GAA 1769/4885MAPT 1760/4885 |
| US-11560389-B2 | Heterocyclic inhibitors of monocarboxylate transporters | SLC16A1, SLC16A3, SLC16A7 | GAA 1769/4885MAPT 1760/4885 |
| US-20190330228-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | SLC16A1, SLC16A3, SLC16A7 | GAA 2114/4885MAPT 1112/4885 |
| US-10329303-B2 | Heterocyclic inhibitors of monocarboxylate transporter | SLC16A1, SLC16A3, SLC16A7 | GAA 2031/4885MAPT 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.